Biocon's breast cancer biosimilar wins EU approval
The European Commission has approved Pebrilzo, Biocon's biosimilar of the breast cancer drug pertuzumab. What the 18 Nov filing says and leaves out.
Jio Financial puts ₹123 crore into Jio BlackRock AMC
Jio Financial Services and BlackRock have each bought ₹123 crore of new shares in Jio BlackRock Asset Management, their 50:50 venture. What the filing says.
NALCO and RUSAL to explore scandium from red mud
National Aluminium Company has signed an MoU with Russian aluminium maker RUSAL to explore recovering scandium from red mud. What the filing says.
Titagarh Rail wins ₹65.38 crore traction motor order
Titagarh Rail Systems has a ₹65.38 crore order from Chittaranjan Locomotive Works for traction motors for WAG-9 locomotives. What the filing says.
Piramal Pharma moves to fully own Yapan Bio
Piramal Pharma has exercised its call option to buy the remaining 26% of Yapan Bio, taking it to 100%. The price and date are not final. What the filing says.
Exide cuts Ulric stake to 26.07% after wind project delay
Exide Industries has reduced its holding in Ulric Renewables from 39.08% to 26.07% after a 10.5 MW Maharashtra wind project missed its start date.
Caplin Point: US FDA flags its injectables plant
The US FDA has classified Caplin Steriles' injectable and eye-care plant at Gummidipoondi as Official Action Indicated. What the 17 Nov filing says.
This page is educational research based on company filings. It is not a recommendation to buy or sell any security or fund, or personalised investment advice. Investments in securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, enlistment with IAASB and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
